Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma

• Verfasst von: Matull, Johanna [VerfasserIn]
• Verfasst von: Placke, Jan-Malte [VerfasserIn]
• Verfasst von: Lodde, Georg Christian [VerfasserIn]
• Verfasst von: Zaremba, Anne [VerfasserIn]
• Verfasst von: Utikal, Jochen [VerfasserIn]
• Verfasst von: Terheyden, Patrick [VerfasserIn]
• Verfasst von: Pföhler, Claudia [VerfasserIn]
• Verfasst von: Herbst, Rudolf [VerfasserIn]
• Verfasst von: Kreuter, Alexander [VerfasserIn]
• Verfasst von: Welzel, Julia [VerfasserIn]
• Verfasst von: Kretz, Julia [VerfasserIn]
• Verfasst von: Möller, Inga [VerfasserIn]
• Verfasst von: Sucker, Antje [VerfasserIn]
• Verfasst von: Paschen, Annette [VerfasserIn]
• Verfasst von: Livingstone, Elisabeth [VerfasserIn]
• Verfasst von: Zimmer, Lisa [VerfasserIn]
• Verfasst von: Hadaschik, Eva [VerfasserIn]
• Verfasst von: Ugurel, Selma [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Verfasst von: Thielmann, Carl Maximilian [VerfasserIn]
• Verfasst von: Griewank, Klaus [VerfasserIn]
• Titel: Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma
• Verf.angabe: Johanna Matull, Jan-Malte Placke, Georg Lodde, Anne Zaremba, Jochen Utikal, Patrick Terheyden, Claudia Pföhler, Rudolf Herbst, Alexander Kreuter, Julia Welzel, Julia Kretz, Inga Möller, Antje Sucker, Annette Paschen, Elisabeth Livingstone, Lisa Zimmer, Eva Hadaschik, Selma Ugurel, Dirk Schadendorf, Carl Maximilian Thielmann and Klaus Georg Griewank
• E-Jahr: 2024
• Jahr: 05 June 2024
• Umfang: 11 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 27.11.2024
• Titel Quelle: Enthalten in: Frontiers in immunology
• Ort Quelle: Lausanne : Frontiers Media, 2010
• Jahr Quelle: 2024
• Band/Heft Quelle: 15(2024), Seite 1-11
• ISSN Quelle: 1664-3224
• DOI: doi:10.3389/fimmu.2024.1383125
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: BAP1
• Sach-SW: immunotherapy IGEA Clinical Biophysics
• Sach-SW: Merck Sharp & Dohme
• Sach-SW: Mutation profiling
• Sach-SW: non-uveal melanoma
• Sach-SW: Novartis
• Sach-SW: Pierre Fabre
• Sach-SW: Uveal Melanoma
• K10plus-PPN: 190963087X

Abstract

Background: Screening for gene mutations has become routine clinical practice across numerous tumor entities, including melanoma. BAP1 gene mutations have been identified in various tumor types and acknowledged as a critical event in metastatic uveal melanoma, but their role in non-uveal melanoma remains inadequately characterized. Methods: A retrospective analysis of all melanomas sequenced in our department from 2014-2022 (n=2650) was conducted to identify BAP1 mutated samples. Assessment of clinical and genetic characteristics was performed as well as correlations with treatment outcome. Results: BAP1 mutations were identified in 129 cases and distributed across the entire gene without any apparent hot spots. Inactivating BAP1 mutations were more prevalent in uveal (55%) compared to non-uveal (17%) melanomas. Non-uveal BAP1 mutated melanomas frequently exhibited UV-signature mutations and had a significantly higher mutation load than uveal melanomas. GNAQ and GNA11 mutations were common in uveal melanomas, while MAP-Kinase mutations were frequent in non-uveal melanomas with NF1, BRAF V600 and NRAS Q61 mutations occurring in decreasing frequency, consistent with a strong UV association. Survival outcomes did not differ among non-uveal melanoma patients based on whether they received targeted or immune checkpoint therapy, or if their tumors harbored inactivating BAP1 mutations. Conclusion: In contrast to uveal melanomas, where BAP1 mutations serve as a significant prognostic indicator of an unfavorable outcome, BAP1 mutations in non-uveal melanomas are primarily considered passenger mutations and do not appear to be relevant from a prognostic or therapeutic perspective.